Quanterix, a diagnostics company focused on developing and commercialising high sensitivity tests, has said that its technology is shown to be more than 1,000 times more sensitive than standard methods with potential for broad application to measure biomarkers in prostrate cancer, autoimmune and neurological diseases.

See the article here:
Quanterix Technology More Sensitive Than Standard Methods: New Study